Literature DB >> 12167381

Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.

Bodo Schwartzkopff1, Michael Fassbach, Beate Pelzer, Michael Brehm, Bodo E Strauer.   

Abstract

BACKGROUND AND AIMS: Left ventricular (LV) dilation and myocardial remodelling are hallmarks of heart failure in idiopathic dilated cardiomyopathy (DCM). Interstitial collagen is essential for LV integrity and function while degradation of collagen by collagenases, especially matrix-metalloproteinases (MMPs), are suggested to contribute to ventricular dilation. In the present study, serological markers of collagen metabolism were investigated. METHODS AND
RESULTS: Serum levels of MMP-1 and its inhibitor (TIMP-1), the markers for collagen degradation type I (collagen carboxyterminal telopeptide (ICTP)) and synthesis (carboxyterminal propeptide of type I procollagen (PICP)) were quantified by ELISA and RIA of 43 patients with DCM and 47 age-matched control subjects. Free MMP-1 serum concentration was significantly increased in the DCM group (5.29+/-0.83 vs. 2.22+/-0.29 ng/ml; P=0.01) as well as the free TIMP-1 concentration (206.54+/-12.65 vs. 181.44+/-8.55 ng/ml; P=0.05). The free MMP-1/TIMP-1-ratio was higher in DCM than in the control group (0.030+/-0.005 vs. 0.012+/-0.001; P=0.01). ICTP was significantly increased (7.60+/-1.21 vs. 3.44+/-0.19 microg/l; P<0.001). PICP was not significantly increased (125.29+/-8.93 microg/l vs. 113.11+/-5.47 microg/l; P=n.s.). Free MMP-1 and MMP-1/TIMP-1-ratio correlated with LV end diastolic diameter [cm/m(2) body surface area (BSA)] (r=0.28; P=0.03 and r=0.34; P=0.01, respectively) as well as with cardiac index (CI) (r=-0.32; P=0.04 and r=-0.33; P=0.04, respectively) in patients with DCM.
CONCLUSION: Serum markers of collagen degradation are elevated and might be valuable markers for progression of LV dilation in patients with DCM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167381     DOI: 10.1016/s1388-9842(02)00092-2

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  27 in total

1.  Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.

Authors:  M Fassbach; B Schwartzkopff
Journal:  Z Kardiol       Date:  2005-05

2.  Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy.

Authors:  Tain-Yen Hsia; Jeremy M Ringewald; Robert E Stroud; Nadia Roessler; Nidhi Kumar; Scott T Reeves; Francis G Spinale
Journal:  Cardiol Young       Date:  2010-10-27       Impact factor: 1.093

3.  The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Duchenne Muscular Dystrophy Cardiomyopathy.

Authors:  Jonathan H Soslow; Meng Xu; James C Slaughter; Kimberly Crum; Joshua D Chew; W Bryan Burnette; Yan Ru Su; Kelsey Tomasek; David A Parra; Larry W Markham
Journal:  J Card Fail       Date:  2019-02-11       Impact factor: 5.712

Review 4.  Screening for ventricular remodeling.

Authors:  Douglas S Lee; Thomas J Wang; Ramachandran S Vasan
Journal:  Curr Heart Fail Rep       Date:  2006-04

5.  Clinical significance of cathepsin L and cathepsin B in dilated cardiomyopathy.

Authors:  Siddharth Mehra; Manish Kumar; Mansi Manchanda; Ratnakar Singh; Bhaskar Thakur; Neha Rani; Sudheer Arava; Rajiv Narang; Dharamvir Singh Arya; Shyam S Chauhan
Journal:  Mol Cell Biochem       Date:  2017-01-10       Impact factor: 3.396

6.  Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.

Authors:  Marcus Franz; Bernhard R Brehm; Petra Richter; Katja Gruen; Dario Neri; Hartwig Kosmehl; Khosro Hekmat; Andre Renner; Jan Gummert; Hans R Figulla; Alexander Berndt
Journal:  J Mol Histol       Date:  2010-03-16       Impact factor: 2.611

7.  Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged >=65 years with heart failure.

Authors:  Willem J Kop; John S Gottdiener; Christopher R deFilippi; Eddy Barasch; Stephen L Seliger; Nancy S Jenny; Robert H Christenson
Journal:  Circ Heart Fail       Date:  2012-06-08       Impact factor: 8.790

8.  Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy.

Authors:  Jose María Tolosana; Lluís Mont; Marta Sitges; Antonio Berruezo; Victoria Delgado; Bàrbara Vidal; David Tamborero; Manel Morales; Montserrat Batlle; Eulalia Roig; M Angeles Castel; Félix Pérez-Villa; Miguel Godoy; Josep Brugada
Journal:  Eur J Heart Fail       Date:  2010-04-01       Impact factor: 15.534

9.  Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases.

Authors:  Dawn A Delfín; Kara E Zang; Kevin E Schill; Nikita T Patel; Paul M L Janssen; Subha V Raman; Jill A Rafael-Fortney
Journal:  Neuromuscul Disord       Date:  2012-06-29       Impact factor: 4.296

10.  Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.

Authors:  Dominic Kelly; Sohail Q Khan; Matt Thompson; Gillian Cockerill; Leong L Ng; Nilesh Samani; Iain B Squire
Journal:  Eur Heart J       Date:  2008-07-08       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.